Tamara Wright
Physician Assistant · Wenatchee, WANPI 1710911839
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 351 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Novo Nordisk at 48.0% of the total. Among physician assistant clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Boehringer Ingelheim$381
- Lilly USA, LLC$368
- Amgen$302
- Xeris Pharmaceuticals, Inc.$278
- Sanofi-aventis U.S. LLC$224
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,349100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 188 | $3,053 |
| Boehringer Ingelheim | 22 | $381 |
| Lilly USA, LLC | 18 | $368 |
| Amgen(2 entities) | 14 | $302 |
| Xeris Pharmaceuticals, Inc. | 16 | $278 |
| Sanofi-aventis U.S. LLC | 12 | $224 |
| Tandem Diabetes Care, Inc. | 8 | $209 |
| Dexcom, Inc. | 5 | $187 |
| Ascensia Diabetes Care US Inc. | 3 | $182 |
| Insulet Corporation | 7 | $149 |
| Abbott | 8 | $138 |
| Bayer | 7 | $123 |
| AstraZeneca | 8 | $123 |
| AbbVie | 8 | $121 |
| Medtronic | 5 | $75 |
| Sanofi | 2 | $66 |
| Radius Health, Inc. | 3 | $60 |
| Merck | 3 | $47 |
| Corcept Therapeutics | 2 | $45 |
| Novartis | 2 | $41 |
| Zealand Pharma US, Inc. | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $23 |
| Clarus Therapeutics Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| Vistapharm, Inc. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| GSK | 1 | $17 |
| Pharming Healthcare, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$120
- t-slim insulin pump$104
- Ozempic$102
How this compares
$6,361 in reported general payments places this provider in the 95th percentile of 2,741 physician assistant providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 205 | $280,921 |
| MounjaroTirzepatide | 162 | $225,120 |
| JardianceEmpagliflozin | 130 | $136,301 |
| Tresiba Flextouch U-200Insulin Degludec | 116 | $122,006 |
| Humalog Kwikpen U-200Insulin Lispro | 29 | $70,912 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $69,127 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 43 | $64,983 |
| TrulicityDulaglutide | 52 | $64,640 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 41 | $57,740 |
| FarxigaDapagliflozin Propanediol | 40 | $49,166 |
| RybelsusSemaglutide | 37 | $47,801 |
| Tresiba Flextouch U-100Insulin Degludec | 66 | $36,306 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 31 | $30,682 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 28 | $30,544 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 12 | $30,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Tresiba | $3,053 | $356,680298 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $368 | $328,760311 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $381 | $166,984161 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $224 | $63,75175 claims |
| AstraZenecaFarxiga | $123 | $49,16640 claims |
| MerckJanuvia | $47 | $22,51924 claims |
| AbbVieSynthroid | $121 | $8,515110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,741 physician assistant providers in Washington.
Other physician assistant in Wenatchee
- Jill KandoraShoreline$437K
- Jeannette HartRichland$263K
- Lance KeckTacoma$162K
- Erinn KingSeattle$129K
- Christy VathSeattle$75K
- Scott TaylorMercer Island$71K
- Gina FragioneGraham$69K
- Regan BrownSpokane$56K
- Justin ChapinSeattle$40K
- Susan DuffyBellevue$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.